What I’m Reading

February 2022

  • Endpoints @JPM: Dealmaking in 2022: What’s Big Pharma looking for and what is it willing to pay?
    • Dealmaking in biotech and pharma may get bigger as capital becomes less abundantly available; FTC delays may be a wildcard
    • Pharma is looking for: biologics, cell therapies, gene therapies, AI/ML to reduce risk and pipeline failure rates. Interest in early stage discovery and development deals.
    • Pharma wants in a partnership: willingness to communicate upfront risks and failures, good cultural fit, thinking about CMC upfront (particularly for complex biologics therapies).
    • Tags: BD, Biologics, Biotech, Deals, Pharma, Partnering

January 2022

%d bloggers like this: